요검사 시장 : 제품 유형별, 검사 유형별, 기술별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Urinalysis Market is projected to grow by USD 6.78 billion at a CAGR of 6.85% by 2032.

Urinalysis Market Executive Summary

Urinalysis is a foundational diagnostic workflow used to screen, diagnose, and monitor urinary tract infections, kidney disease, diabetes-related complications, pregnancy-related conditions, liver disorders, and metabolic abnormalities. The market spans reagent strips, urine chemistry analyzers, sediment analyzers, microscopy systems, consumables, point-of-care testing, and laboratory information system connectivity.

Demand is supported by high chronic disease burden and routine clinical use. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, and the U.S. CDC estimates that more than 37 million U.S. adults have chronic kidney disease. These epidemiological realities make urine testing a high-volume, cost-effective component of preventive care, emergency medicine, nephrology, obstetrics, occupational health, and long-term disease management.

Transformative Shifts in the Urinalysis Landscape

The urinalysis landscape is shifting from manual dipstick interpretation and microscopy toward automated, connected, and quality-controlled testing ecosystems. Clinical laboratories are prioritizing analyzers that reduce hands-on time, improve result standardization, and integrate with laboratory information systems to support high-throughput workflows.

Point-of-care urinalysis is also expanding in primary care, urgent care, pharmacies, and remote clinics as health systems seek faster triage and earlier detection. At the same time, regulatory expectations for accuracy, traceability, and cybersecurity are increasing, making validation, operator training, and data governance critical differentiators for urinalysis solution providers.

Cumulative Impact of Artificial Intelligence in Urinalysis

Artificial intelligence is changing urinalysis by improving image-based sediment classification, flagging abnormal patterns, supporting reflex testing decisions, and reducing variability in microscopic interpretation. AI-enabled urine sediment analyzers can help laboratories manage workforce shortages by automating repetitive review tasks while escalating complex cases to trained professionals.

The cumulative impact of AI is strongest when algorithms are paired with verified clinical data, instrument calibration, and human oversight. In practice, AI can support earlier detection of kidney injury, urinary tract infection indicators, hematuria, crystalluria, and cellular abnormalities; however, adoption depends on clinical validation, explainability, privacy compliance, and integration into existing diagnostic pathways.

Key Regional Insights Across Urinalysis Markets

North America remains a mature urinalysis market supported by high healthcare spending, established laboratory networks, strong adoption of point-of-care diagnostics, and chronic kidney disease screening initiatives. Europe benefits from structured healthcare systems, quality-driven laboratory procurement, and the European Union's evolving in vitro diagnostic regulatory framework, while Latin America is expanding access through hospital modernization, private diagnostics growth, and rising diabetes and kidney disease awareness.

Asia-Pacific is a major demand region because of large patient populations, expanding healthcare infrastructure, aging demographics, and rising routine testing needs across China, India, Japan, South Korea, Australia, and ASEAN economies. The Middle East is investing in hospital infrastructure, preventive care, and chronic disease programs, particularly across GCC countries. Africa presents long-term opportunity as primary care diagnostics, maternal health services, kidney disease awareness, and infectious disease screening capacity improve across urban and regional settings.

Key Group Insights for Urinalysis Demand

ASEAN demand is shaped by expanding primary care, urban hospital investment, and growing diabetes screening needs across countries such as Indonesia, Thailand, Vietnam, Malaysia, and the Philippines. GCC markets are influenced by high noncommunicable disease prevalence, national healthcare modernization plans, and procurement preference for automated, connected diagnostic systems.

The European Union emphasizes compliance, clinical evidence, traceability, and quality systems under the IVDR environment, which affects reagent, analyzer, and software commercialization. BRICS countries represent scale-driven demand from large populations, public health needs, and expanding diagnostic infrastructure, while the G7 remains important for premium automation, AI-assisted diagnostics, reimbursement sophistication, and early adoption of connected laboratory platforms. NATO-aligned markets often overlap with high-standard procurement environments where resilience, cybersecurity, and supply continuity are increasingly important.

Key Country Insights in Urinalysis

The United States leads in automated urinalysis adoption through large reference laboratories, hospital systems, urgent care networks, and value-based care initiatives. Canada shows steady demand driven by public healthcare coverage and chronic disease monitoring, while Mexico and Brazil continue to expand diagnostic access through private laboratory chains, hospital investment, and public health programs. In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize laboratory efficiency, regulatory compliance, and standardized workflows, while Russia maintains demand through hospital and regional diagnostic networks.

China and India are high-potential urinalysis markets due to population scale, diabetes burden, hospital expansion, and increasing use of routine screening. Japan and South Korea are advanced markets with strong automation adoption and aging populations requiring kidney and metabolic monitoring. Australia benefits from robust primary care, pathology infrastructure, and preventive health programs that support consistent urinalysis utilization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize product portfolios that combine reagent reliability, analyzer automation, sediment imaging, point-of-care usability, and secure connectivity. Manufacturers and distributors can strengthen competitiveness by demonstrating workflow savings, operator consistency, quality control performance, and interoperability with laboratory information systems.

Commercial strategy should be localized by care setting and reimbursement environment. Mature markets require evidence, compliance, cybersecurity, and total cost of ownership messaging, while emerging markets value affordability, service support, training, and scalable platforms. AI-enabled solutions should be introduced with transparent validation data, clinician education, and clear escalation protocols.

Research Methodology

This executive summary is built from secondary research, epidemiological indicators, regulatory analysis, clinical workflow assessment, and triangulation across diagnostics, nephrology, diabetes care, point-of-care testing, and laboratory automation. Key reference domains include public health agencies, peer-reviewed clinical literature, international disease-burden datasets, regulatory frameworks, and product portfolio analysis.

The methodology emphasizes data-backed interpretation rather than unverified market sizing. Insights are validated through cross-comparison of disease prevalence, testing utilization drivers, healthcare infrastructure maturity, procurement trends, regulatory requirements, and technology adoption patterns across regions, groups, and priority countries.

Conclusion

Urinalysis remains one of the most widely used diagnostic tools because it is low-cost, rapid, and clinically relevant across preventive care, acute care, and chronic disease management. Demand is being reinforced by diabetes and kidney disease prevalence, aging populations, urinary tract infection testing needs, pregnancy monitoring, and increased use of automated and point-of-care diagnostics.

The next phase of competition will favor organizations that combine analytical accuracy, workflow efficiency, digital connectivity, AI-assisted interpretation, and strong regulatory compliance. Stakeholders that align technology with clinical evidence, cybersecurity expectations, and localized access needs will be best positioned in the global urinalysis market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinalysis Market, by Product Type

• 7.1. Urinalysis Dipsticks
• 7.2. Urine Analyzers
• 7.3. Consumables
  • 7.3.1. Reagents
  • 7.3.2. Cups & Containers
  • 7.3.3. Calibration Materials
• 7.4. Point-of-Care Urinalysis Devices
  • 7.4.1. Portable Analyzers
  • 7.4.2. Handheld Devices
• 7.5. Microscopy Systems

8. Urinalysis Market, by Test Type

• 8.1. Physical Examination
• 8.2. Chemical Examination
• 8.3. Microscopic Examination

9. Urinalysis Market, by Technology

• 9.1. Optical Technology
• 9.2. Reflectance Photometry
• 9.3. Flow Cytometry
• 9.4. Digital Imaging Analysis
• 9.5. AI-Based Urinalysis Systems
• 9.6. IoT-Enabled Urinalysis Systems

10. Urinalysis Market, by Application

• 10.1. Disease Diagnosis
  • 10.1.1. Kidney Disorders
  • 10.1.2. Urinary Tract Infections
  • 10.1.3. Liver Diseases
• 10.2. Pregnancy Testing
• 10.3. Drug Screening
• 10.4. Routine Health Checkups
• 10.5. Chronic Disease Monitoring

11. Urinalysis Market, by End User

• 11.1. Clinics
• 11.2. Home Care Settings
• 11.3. Hospitals
• 11.4. Research & Academics

12. Urinalysis Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Urinalysis Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Urinalysis Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Urinalysis Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 77 Elektronika Kft
• 17.2. Abbott Laboratories
• 17.3. Accurex Biomedical Pvt Ltd
• 17.4. ACON Laboratories Inc
• 17.5. Agappe Diagnostics Ltd
• 17.6. Alphatec Scientific EIRL
• 17.7. Analyticon Biotechnologies GmbH
• 17.8. ARKRAY Inc
• 17.9. Becton Dickinson and Company
• 17.10. Bio-Rad Laboratories Inc
• 17.11. BIOBASE Group
• 17.12. BioCare Corporation
• 17.13. Bioway Biological Technology Co Ltd
• 17.14. Clarity Diagnostics LLC
• 17.15. Contec Medical Systems Co Ltd
• 17.16. Danaher Corporation
• 17.17. DIALAB GmbH
• 17.18. Dirui Industrial Co Ltd
• 17.19. EKF Diagnostics Holdings plc
• 17.20. Erba Mannheim
• 17.21. F. Hoffmann-La Roche Ltd
• 17.22. High Technology Inc
• 17.23. Medline Industries LP
• 17.24. PZ Cormay SA
• 17.25. Quantimetrix
• 17.26. Randox Laboratories Ltd
• 17.27. Shenzhen Mindray Bio-Medical Electronics Co Ltd
• 17.28. Siemens Healthineers AG
• 17.29. Sysmex Corporation
• 17.30. Teco Diagnostics
• 17.31. Thermo Fisher Scientific Inc
• 17.32. Toyobo Co Ltd
• 17.33. URIT Medical Electronic Co Ltd
• 17.34. YD Diagnostics